Pfizer announced additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate
On Dec. 14, 2021, Pfizer announced final results from an analysis of all 2,246 adults enrolled in its…
On Dec. 14, 2021, Pfizer announced final results from an analysis of all 2,246 adults enrolled in its…
On Dec. 10, 2021, the World Health Organization announced interim recommendations for the use of the Janssen Ad26.COV2.S…
On Dec. 9, 2021, CytoDyn announced that it had submitted a Phase 3, randomized, double blind, placebo controlled…
On Dec. 8, 2021, Pfizer and BioNTech announced results from an initial laboratory study demonstrating that serum antibodies…
On Dec. 5, 2021, Sorrento Therapeutics announced the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors…
On Dec. 1, 2021, T2 Biosystems announced that its T2SARS-CoV-2 Panel detected the Omicron COVID-19 variant (B.1.1.529). To…
On Dec. 1, 2021, the California and San Francisco Departments of Public Health confirmed that a recent case…
On Nov. 17, 2021, GlaxoSmithKline and Vir Biotechnology announced U.S. government contracts totalling approximately $1 billion (USD) to…
On Nov. 16, 2021, Pfizer announced it announced it had submitted an Emergency Use Authorization (EUA) of its…
On Nov. 15, 2021, Moderna confirmed that Health Canada had authorized the use of a booster dose of…
On Nov. 15, 2021, Moderna confirmed that Health Canada authorized the use of a booster dose of the…
On Nov. 8, 2021, Regeneron announced that the European Commission had approved the casirivimab and imdevimab antibody cocktail,…
On Nov. 8, 2021, Cocrystal Pharma announced that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral…
On Nov. 5, 2021, Pfizer announced it was investigational novel COVID-19 oral antiviral candidate, PAXLOVID, significantly reduced hospitalization…
On Nov. 5, 2021, Chugai Pharmaceutical, announced that it had obtained approval from the Ministry of Health, Labour…
On Nov. 4, 2021, Novavax announced the completion of its rolling submission to the World Health Organization (WHO)…
On Oct. 29, 2021, research led by scientists at the National Institutes of Health announced they had identified…
On Oct. 28, 2021, Pfizer and BioNTech announced that the U.S. government had purchased 50 million more doses…
On Oct. 26, 2021, BioNTech announce that the Company planned to initiate the construction of the first state-of-the-art…
On Oct. 25, 2021, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
On Oct. 25, 2021, scientists at Oxford University reported that Infection with COVID-19 carried a much higher risk…
On Oct. 21, 2021, Pfizer and BioNTech announced topline results from a Phase 3 randomized, controlled trial evaluating…
On Oct. 19, 2021, the first investigational transplant of a genetically engineered, nonhuman kidney to a human body…
On Oct. 18, 2021, Gilead Sciences announced that the Food and Drug Administration had approved a new low-dose…
On Oct. 18, 2021, Athenex and the Center for Cell and Gene Therapy at Baylor College of Medicine,…
On Oct. 18, 2021, Pfizer and BioNTech announced that the European Medicines Agency’s Committee for Human Medicinal Products…
On Oct. 15, 2021, Pfizer and BioNTech announced they had submitted data supporting the vaccination of children 5…
On Oct. 12, 2021, Lucira Health announced that it had received PSAR approval for its Lucra CHECK IT…
On Oct. 12, 2021, National Resilience announced a strategic collaboration with Children’s Hospital of Philadelphia (CHOP) to implement…
On Oct. 11, 2021, scientists at Washington University School of Medicine in St. Louis announced they had developed…